



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/699,024	10/31/2003	Jagir Razak Jainul Abdeen Hussan	JP920030152US1

39903
 ANTHONY ENGLAND
 PO Box 5307
 AUSTIN, TX 78763-5307



CONFIRMATION NO. 2138
FORMALITIES
LETTER

Date Mailed: 08/15/2006

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>


For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov**

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450

Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*



Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382

PART 2 - COPY TO BE RETURNED WITH RESPONSE



In the United States Patent and Trademark Office

re the application of:)	
Hussan, Jagir Razak Jainul)	
)	
Filed: 10/31/2003)	Group Art Unit: 1645
)	
For: Multisequence Data)	Examiner: Unknown
Representation)	
)	
Application No. 10/699,024)	
)	
Applicant's Docket:)	
JP920030152US1)	

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This reply is responsive to the attached Notice to Comply of August 15, 2006.


On July 28, 2006, Applicant submitted a reply to a Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated June 29, 2006, in which Applicant amended the drawings and the specification of the originally filed application in order to conform them to the correct format. In that reply, Applicant also provided i) a written sequence listing corresponding to the sequence listings in the specification and drawings, and ii) a computer readable copy thereof (compact disk). However, the present Notice to Comply of August 15, 2006, indicates that i) the previously submitted written sequence listing and computer readable copy thereof are not in the proper form, and ii) a required statement regarding no new matter was omitted. The present reply is to correct the written sequence to accompany the specification and computer readable copy thereof and to provide the required statement regarding no new matter.

STATEMENT REGARDING NO NEW MATTER

The information recorded in the enclosed computer readable form is identical to the enclosed written sequence listing. No new matter is included in the amendments to the specification and drawings submitted in Applicant's reply of July 28, 2006 nor in the enclosed written sequence listing and computer readable copy thereof, since the application as originally filed provides support.

Applicant submits that the invention as claimed in the originally filed application is patentably distinct and hereby requests that the Examiner grant allowance and prompt passage of the application to issuance.

Respectfully submitted,



Anthony V.S. England
Attorney for Applicant
Registration No. 35,129
512-477-7165
a@aengland.com

Attachments:

1. Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages)
2. Sequence Listing (printout) (6 pages)
3. Sequence Listing (on CD)